CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for OPKO Health Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

OPKO Health Inc
4400 Biscayne Blvd.
Phone: (305) 575-4181p:305 575-4181 MIAMI, FL  33137  United States Ticker: OPKOPK
Business Summary
OPKO Health, Inc. is a multinational biopharmaceutical and diagnostics company. The Company focuses on leveraging its discovery, development, and commercialization expertise and novel and proprietary technologies. Its segments include pharmaceutical and diagnostics. The pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain, Rayaldee product sales and its pharmaceutical research and development. The diagnostics segment primarily consists of point-of-care operations. Its pharmaceutical business features Rayaldee, a United States Food and Drug Administration (FDA) approved treatment for secondary hyperparathyroidism (SHPT) in adults with stage three or four chronic kidney disease (CKD) and vitamin D insufficiency, and Somatrogon (hGH-CTP), a once-weekly human growth hormone injection. Its NGENLA (somatrogon-ghla), is a once-weekly, human growth hormone analog indicated for treatment of pediatric patients aged three years and older.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/202412/31/2023YesYes--Yes

Industries
SIC Code Description
2834 Pharmaceutical preparations
8071 Medical laboratories
8731 Commercial physical and biological research
3841 Surgical and medical instruments and apparatus
5122 Drugs, drug proprietaries, and druggists' sundries

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board, Chief Executive Officer PhillipFrost 87 3/27/2007 3/27/2007
President, Vice Chairman of the Board Elias A.Zerhouni 73 5/9/2022 5/9/2022
Vice Chairman of the Board, Chief Technical Officer Jane H.Hsiao 76 5/4/2007 2/1/2007
10 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
OPKO BIOLOGICS LTD. 7 GOLDA MEIR STREET NES ZIONA
OPKO CHILE S.A. AGUSTINAS 460, PISO 10 SANTIAGO CHILE
OPKO DIAGNOSTICS LLC 4400 BISCAYNE BLVD MIAMI FL US
9 additional Subsidiary records available in full report.

Business Names
Business Name
ALS Distribuidora Limitada
Arama Natural Products Distribuidora, Ltda
Bio-Reference Laboratories Inc.
27 additional Business Names available in full report.

General Information
Number of Employees: 3,930 (As of 12/31/2023)
Outstanding Shares: 682,483,029 (As of 11/1/2024)
Shareholders: 368
Stock Exchange: NASD
Federal Tax Id: 752402409
Email Address: info@cytoclonal.com


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, November 20, 2024